Arpraziquantel

Arpraziquantel
Clinical data
Other names	(R)-Praziquantel
Drug class	Anthelmintic
ATC code	P02BA03 (WHO) ;
Identifiers
CAS Number	57452-98-9;
PubChem CID	445900;
DrugBank	DB11749;
ChemSpider	393394;
UNII	WF15T5925V;
KEGG	D12741;
ChEMBL	ChEMBL1235551;
PDB ligand	PZQ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID80904739 ;
Chemical and physical data
Formula	C19H24N2O2
Molar mass	312.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1;
	InChI InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1; Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N;

Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, a medication which is under investigation for the treatment of schistosomiasis in young children with less side effects than the racemate.^[1]

Society and culture

Legal status

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.^[1] The applicant for this medicinal product is Merck Europe B.V.^[1] It is intended exclusively for markets outside the European Union.^[1]

Names

Arpraziquantel is the International nonproprietary name.^[2]

References

^ ^a ^b ^c ^d "Arpraziquantel". European Medicines Agency. 14 December 2023. Archived from the original on 20 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

Society and culture

Legal status

Names

References

Further reading